Panacea Biotec share price today

Panacea Biotec Ltd's share price was ₹344.80 at the close on 4 November 2026. It has been falling for 6 weeks. That is 13.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹311 and ₹608, and at that close it sat 11% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Panacea Biotec Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running.

Over the last 11 years the share price moved +288% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, foreign funds (FIIs) raised their stake for 5 quarters in a row and highest quarterly revenue in 15 quarters.

1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row

   From 1.2% to 2.5% of the company by the September 2026 quarter.

2. Foreign funds (FIIs) raised their stake for 5 quarters in a row

   From 0.8% to 2.8% of the company by the September 2026 quarter.

3. Highest quarterly revenue in 15 quarters

   Revenue of ₹200 crore in the June 2026 quarter is the highest of the last 15 quarters.

For April to June 2026 (the quarter ended 30 June 2026), Panacea Biotec reported revenue of ₹200 crore, up 19.7% from ₹167 crore a year earlier, and a profit of ₹2.20 crore, down 44.4% from ₹3.96 crore.

Panacea Biotec results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Panacea Biotec closed at ₹344.80 on 4 November 2026, down 16.8% from ₹414.60 a year earlier (7 November 2025) and up 61.4% over five years. Its highest weekly close since March 2016 was ₹607.75 on 9 June 2026.

Panacea Biotec share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Panacea Biotec closed at ₹344.80, up 10.1% on the week and down 4.0% on the month. Results for April to June 2026: Revenue up 19.7% and profit down 44.4% on a year earlier.

Panacea Biotec has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Panacea Biotec Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Panacea Biotec is on one of our India lists: Pharma stocks.

Panacea Biotec Ltd earned ₹2.2 Cr of net profit in the Jun 2026 quarter, −44.4% on the same quarter a year earlier. The full FY26 year was a loss of ₹7.0 Cr. That is 1.1% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr. 7 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Why profit moved: revenue changed +19.7% on a year earlier and the margin moved +3.5 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed −151.4% and revenue +10.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

Panacea Biotec Ltd reported ₹200 Cr of revenue in the Jun 2026 quarter, +19.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −0.2% a year on average. The last full year, FY26, came in at ₹640 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹673 Cr.

FY26 revenue was ₹640 Cr, +14.5% on the year before.

Recent pace: the last four quarters grew +10.6% on average, against −0.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.3%, against +11.0% a year over the last 8 quarters (stabilising).

Panacea Biotec Ltd's operating margin was 2.8% in the Jun 2026 quarter, 3.5 percentage points higher than the same quarter a year ago. Across 13 years it has been between −29.0% and 17.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.5 percentage points on the year while gross margin changed −4.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 2 years, 0% of Panacea Biotec Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹17.0 Cr of operating cash against −₹7.0 Cr of profit. After ₹58.0 Cr of spending on assets, free cash was −₹41.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 0% of profit came in as cash: the cash cycle got 126 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 126 days longer. The next section looks at where the cash is stuck.

Panacea Biotec Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 46 days in FY26, up from −80 days in FY21. It spent ₹183 Cr on assets over the last 3 years. Customers take 42 days to pay, and stock sits for 251 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹640 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹81.0 Cr is tied up in the business at any time.

FY26: customers took 42 days to pay and stock sat for 251 days, about 8.3 months of sales sitting as stock, for a full cycle of 46 days, longer than FY21's −80.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 251 days. Customers pay about 42 days after that. Suppliers are paid at 247 days. Together that makes the 46-day cycle.

Spending on assets: ₹183 Cr over the last 3 years, against ₹105 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹144 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Panacea Biotec Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Panacea Biotec Ltd at 3.3× its FY26 revenue of ₹640 Cr. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Panacea Biotec Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Panacea Biotec Ltd earned a ROCE of −2% in FY26. That is up from a low of −16% in FY19. Its return on capital used (ROIC) is 15.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a −1.1% net margin and 0.51× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −1.1% net margin × 0.51× asset turnover × 1.51× leverage (assets divided by equity) ≈ −0.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −3.9% − 12.0% = −15.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Panacea Biotec Ltd has total debt of ₹24.0 Cr against shareholder equity of ₹829 Cr as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Foreign institutions raised their stake in Panacea Biotec Ltd by 2.4 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.8% of the company. Domestic institutions moved +1.3 points over the same period, to 2.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +2.4 points over 8 quarters, to 2.8%; Domestic institutions: +1.3 points over 8 quarters, to 2.5%; Promoters: −0.4 points over 8 quarters, to 72.5%.

Why the owners changed: foreign institutions drove it (+2.4 points), together with domestic institutions (+1.3 points). They raised their stake step by step.